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Smuy We performed a phase II study with mitoxantrone in patients with arcinoid tumours, islet cell
tumours and medullary carcinomas of the thyroid Thirty-five eligible patients received mitoxantrone
12mg m2 i.v. every 3 weeks. Among 18 previously untreated patients, three responded (17%, 95%
CI=4-41%); no esponses were achieved in 17 previously trated patients. Of the 21 patients who had
aucinoid tumours, 11 were previously untreated and two ahieved a response (18%, 95% CI=2-52%).
Overall response rate was 9% (95% CI = 2-23%). At a median follow-up of 43 months, median overall
survival was 16 months. The median survival of 21 patients with a normal alline phosphatase was 29
months and 9 months for 14 patients with elevated serum levels (P = 0.005). A similar observation was noticed
for ?-glutamyltransferase (P = 0.007). We concuded that mitoxantrone is not active in APUD tumours.
Elevated alkahne phosphatase and ?-glutamytransferase are associated with a poor prognosis.
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Carcinoid tumours, islet cell tumours and medullary car-
cinomas of the thyroid are considered to have common cell
origin from the neural crest (Pearse, 1969). The three
tumours share the ability to dycarboxylate amines (APUD
tumours). Aggressive surgical resection of the bulk of the
disease is recommended. In patients with unresectable metas-
tatic tumours, antihormonal measures and finally cytotoxic
chemotherapy may improve symptoms. Because of the
similar properties of these cell types, advanced disease is
often treated by common chemotherapy protocols (Kessnger
et al., 1983; Saltz el al., 1993).
The use of single drugs or combination chemotherapy
regimens result in no response to a 40%/ resonse rate at best.
However, it is suggested by experiecd investigators that
patients should undergo cytotoxic treatment as soon as
symptoms appear that cannot be controlled otherwise
(Moertel, 1987). The best response rates for carcinoid
tumours have been achieved with 5-fluorouracil, doxorubicin
and streptozotocn (between 20 and 30%). Combination
chemotherapy is not better than single drug. The best treat-
ment results for islet cell tumours have been achieved with a
combination of streptozotocin plus doxorubicin (Moertel et
al., 1992). However, severe nausea and vomiting with this
regmien compromised the patients' quality of life, and other
combinations with better therapeutic effectiveness and better
clinical tolerance are needed.
Mitoxantrone seemed worth testing in APUD tumours
because of its low gastrointestinal toxicity and similarity to
doxorubicin, which is known to be active in this context
(Moertel et al., 1982). We performed a phase II study of
mitoxantrone to determine its activity in patients with APUD
tumours.
Paliem ad
Patients admitted to this non-randomised study had his-
tologically proven islet cell carcinoma, carcinoid tumours or
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medullary carcinomas of the thyroid not amenable to
surgery. The sample size caculation was based on the two-
stage Gehan (1961) design, aiming to include 14 patients and-
then adding other paients for each response seen in the first
stage. This guarantees that the probability of an active treat-
ment (real response rate > 20%) exhibiting no responses in
the first 14 patients (that is a false negative result) is 0.05 and
allows the therapeutic effectiveness to be estimated with a
standard error of 10%. Prior chemotherapy was allowed
because at that time some members of the EORTC Gastro-
Intinal Cancer Cooperative Group felt that a trial with a
known active drug should be done prior to treatment with a
new drug. Only patients with measurable metastatic progres-
sive disease were entered. Informed consent was obtained
according to poLicies applied in the individual partipating
institutions. No pharmaceutical firm was involved in the
study.
Patients were excluded if they were older than 75, had
received prior treatment with doxorubicin or prior
radiotherapy to the single indicator lesion or had previous or
other cancer. None of the patients received concurrent San-
dostatin. At the start of chemotherapy the haematological
status had to be favourable (white blood cells more than
3.5 x 109 '- or platelets more than 00 x 1091-'), bilirubin
less than 25 amol 1- , creatinine clearance more than
60ml min'. The extent of measurable disease was as
before treatment and after three and six treatment cycles.
Patients received mitoxantrone in a dose of 12 mgm-2 i.v.
over 30min (in 100ml of 5% dextrose solution) repeated
every 3 weeks. Concurrent administration of a standard
antiemetic was permitted. Drug administration was post-
poned for up to 3 weeks in the absence offull haematological
recovery from the previous course (leucocytes more than
30000 1d' and platelets more than 100000pl'). If full
haematological recovery had still not occurred, dose adjust-
ments were made according, to the lowest value of the
leucocyte and platelet counts determined on day 15. Patients
received at least three courses to be evaluable unless it was
not in their best interest. Response was assess using stan-
dard WHO (1979) criteria and evaluated after three cycles of
treatment, unless severe toxicity or disease progression
supervened and it was deemed to be against the patient's bestJP Io i m r apudonis
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interests to continue. Early progression after one cycle was
evaluated as such.
Resuls
Between April 1985 and March 1990, 37 patients were
enrolled in the study. Two patients were ineligible, one
patient with no information after registration and another
because of inadequate histology (follicular thyroid car-
cinoma). The present analysis is based on 35 eligible patients.
Table I presents patient and tumour characteristics at entry.
Median age at entry was 58.6 years (range 21.9-75). Time
from diagnosis varied between 2 days and 12 years with a
median of 19 months.
Mitoxantrone starting dosage (mg) varied between 16 and
25 (median 20). Number of treatment cycles varied between 1
and 15 (median 6). Eight patients had a dose reduction
defined as a dose less than 90% of the first dose during at
least one cycle (reductions for treatment-related toxicity). The
total dose of mitoxantrone (mg) varied between 18 and 314
(mean ±s.d. = 117 + 77, median = 108). When corrected for
the surface area, the dose of mitoxantrone (mg m-) varied
between 12 and 177 (median 61).
Side-effects of mitoxantrone were mild and included
nausea and vomiting (grade 2, 23%; grade 3, 3%), stomatitis
grade 1 (1 patient) and haemorrhage grade 2 and 4 occurred
once. Other registered side-effects were infection, grade 2
(two patients), hair loss grade 1 (six patients) grade 2 (3
patients), leucopenia grade 3 in nine patients (26%) and
grade 4 in two (6%).
Table I Patient and tumour characteristics at entry (%)
Sex
Males
Females
Tumour type
Islet cell tumours
Carcinoid tumours
Medullary carcinomas of the thyroid
Performance status (WHO)
0-1
2-3
Symptoms of endocrine hyperfunction
Prior surgery
No
Yes curative
Yes palliative
Prior radiotherapy
Prior chemotherapy
Prior hormone therapy
yGT, WHO grade'
0
2
4
Unknown
'0, < 1.25 N; 1, 1.26-2.5 N; 2, 2.6-
> 10 N (N, normal value).
21 (60)
14 (40)
9
21
5
(26)
(60)
(14)
27 (77)
8 (23)
18 (51)
11
10
14
(31)
(29)
(40)
3 (9)
17 (49)
5 (14)
17
7
7
3
(49)
(20)
(20)
(9)
(3)
-5.ON; 3, 5.1-10.ON; 4,
Table H presents the response data. Three patients (9%,
95% CI = 2-23%) achieved a partial remission. None of the
responders had prior radiotherapy or chemotherapy. In the
18 previously untreated patients the response rate was 17%
(95% CI = 4-41%). Duration of response was 8.5, 13.8 and
16.6 months. Two out of eleven patients with untreated
carcinoid tumours responded (18%, 95% CI = 2-52%).
Twenty-six patients died; 22 died from their malignancy,
whereas the case of death was unknown for the other four
patients. At a median follow-up of 43 months, the median
survival of all patients was 16 months. No differences in
survival could be detected between males and females, perfor-
mance status at entry, the present of symptoms of endocrine
hyperfunction, prior surgery, histological tumour type or
levels of aspartate aminotransferase (ASAT) or alanine
aminotransferase (ALAT). However, the survival of patients
with an elevated alkaline phosphatase (WHO 1-4) was
decreased compared with patients with a normal alkaline
phosphatase. The median survival of 21 patients with a
normal alkaline phosphatase was 29 months and for 14
patients with elevated serum levels it was 9 months
(P = 0.005). A similar observation was noticed for y-
glutamyltransferase. Seventeen patients was normal values
survived for 30 months, whereas those with abnormal values
died after a median of 10 months (P = 0.007) (see Figure 1).
No association was found between the presence of liver
metastases and an elevation of these enzymes.
Treatment with mitoxantrone resulted in disease stabilisation
in 43% of the patients. This is not an uncommon result in
this usually slow progressive type of disease. Unfortunately,
partial remissions were rare (9%), and it must be concluded
that mitoxantrone has no important efficacy as a single drug
in patients with APUD tumours. The three responses were
achieved in the group of 18 non-pretreated patients, two of
which occurred in 11 untreated carcinoid tumours (18%), but
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Figwe 1 Duration of survival of patients with a normal ^-
glutamyltransferase (7-GT, WHO 0) or with an elevated ^-
glutamyltransferase (^-GT, WHO 1-4).
Table II Response to treatment according to tumour type (n = 35)
Medadlary
Islet cell Carcimoid carcinomas Total no. of
tumours tumours of the thyroid patients (%
Evaluable patients 9 21 5 35 (100)
Partial remission 2 1 3 (9)
No change 6 7 2 15 (43)
Progression 3 11 1 15 (43)
Early progression 1 (3)
Insufficient data 1 1 (3)
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this response rate was judged to be to low to warrant further
study. In untreated patients combination chemotherapy with
doxorubicin and streptozocin results in response rates of
about 60% (Moertel et al., 1992). The results prove that
chemotherapy can result in tumour shrinkage and that fur-
ther studies are needed to identify new active drugs. T1he role
of biologicals such as interferon-a (IFN-a) with or without
cytotoxic drugs has to be further established (Oberg and
Eriksson, 1991) and new drugs such as paclitaxel (Taxol),
and 2',2'-difluorodeoxicytidine (Gemcitabine) should undergo
phase II testing. Because an established standard treatment is
not available, such a study should preferably be performed in
previously untreated patients aiming at a response rate above
30%.
Prognostic factors that determine outcome in APUD
tumours suitable for chemotherapy are not well known. This
study revealed liver function disturbance as measured by
alkaline phosphatase or y-glutamyltransferase to predict an
unfavourable prognostic outcome in terms of survival.
Future studies should report these patient characteristics as
survival data are used as an end point of treatment efficacy.
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